uniQure N.V. (QURE)

The past six months have seen significant events impacting uniQure N.V.'s stock price, primarily related to its lead gene therapy candidate, AMT-130 for Huntington's disease. On November 3, 2025, uniQure's stock plummeted after the FDA disagreed that Phase I/II data of AMT-130 would support a BLA submission. On March 2, 2026, shares fell further after the FDA rejected the data package for AMT-130 for accelerated approval and recommended a Phase III sham-controlled study. In early March 2026, a senior FDA official publicly criticized uniQure for pushing distorted data, leading to securities class-action lawsuits. Despite these setbacks, sentiment shifted in early March 2026 following news that the FDA official overseeing AMT-130 would step down.

Information regarding demand seasonality for uniQure N.V.'s products and services was not found in the provided search results. As a gene therapy company focused on developing one-time administered treatments for rare and devastating genetic diseases, it is generally unlikely for its products to exhibit typical demand seasonality seen in other industries.

uniQure N.V. is a gene therapy company focused on developing treatments and platforms for genetic and other devastating diseases within the Healthcare sector, specifically in Biotechnology and Drug Discovery. Its major products and pipeline candidates include HEMGENIX, a gene therapy for hemophilia B, AMT-130 for Huntington's disease, AMT-260 for mesial temporal lobe epilepsy, AMT-162 for superoxide dismutase enzyme-amyotrophic lateral sclerosis (ALS), and AMT-191 for Fabry disease. The company also develops gene therapies for cardiovascular diseases in collaboration with Bristol Myers Squibb.

uniQure N.V. is headquartered in Amsterdam, Netherlands, with operations and market reach extending to the United States, the Netherlands, and other countries. It also maintains a manufacturing facility in Lexington, Massachusetts, U.S.

uniQure's brand reputation has been significantly impacted by negative events surrounding its lead gene therapy candidate, AMT-130. Public rebukes from a senior FDA official, accusing the company of presenting distorted data and calling AMT-130 a failed therapy, have severely damaged its standing. These allegations and the FDA's strong recommendation for a Phase III sham-controlled study have led to multiple securities fraud class-action lawsuits against the company, alleging misrepresentation of interactions with the FDA.

uniQure N.V. is predominantly owned by institutional shareholders, with ownership ranging from 66.10% to 120.0% depending on the source. Individual investors hold approximately 17% of the company's stock, while insiders own around 2.53% to 11.34% of the shares. Major institutional owners include Fmr LLC, Avoro Capital Advisors LLC, RTW Investments, LP, Standard Life Aberdeen plc, State Street Corp, JPMorgan Chase & Co, BlackRock, Inc., Two Sigma Investments, LP, and MPM Oncology Impact Management LP. The largest individual shareholder is Bv Foruniqure, owning 7.00% of the company's shares, and CEO Matthew Kapusta directly holds 0.6% of the total shares outstanding.